文献速递抗菌药物管理药物不良反应与药物警戒

奥马环素:新型口服和静脉用氨甲基四环素类抗生素

Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
PubMed 文献 · Drugs · 2020-01-01

奥马环素是每日一次静脉或口服的氨甲基四环素类抗生素,用于急性细菌性皮肤及皮肤结构感染(ABSSSI)和社区获得性细菌性肺炎(CABP)。III期试验OASIS-1、OASIS-2和OPTIC分别证实其相对于利奈唑胺和莫西沙星的非劣效性。FDA已批准用于ABSSSI和CABP,口服制剂可支持序贯治疗。

要点

  • 对ABSSSI和CABP,奥马环素相对于利奈唑胺或莫西沙星显示非劣效性。
  • 口服生物利用度34.5%,口服300 mg与静脉100 mg生物等效。
  • 对携带四环素耐药机制(如TetK、TetM)的菌株仍保持活性。

核心结论

  • 奥马环素对ABSSSI和CABP的疗效非劣效于利奈唑胺和莫西沙星,且具有口服剂型优势。
  • 奥马环素对携带常见四环素耐药机制的细菌分离株仍保持活性。

研究设计与样本

  • 综述总结了奥马环素的化学结构、抗菌活性、药代动力学、动物模型及II/III期临床试验数据。
  • III期试验包括OASIS-1(ABSSSI)、OASIS-2(ABSSSI)和OPTIC(CABP),分别与利奈唑胺和莫西沙星对照。

主要发现

  • 健康受试者中,奥马环素分布容积(Vd)为190–204 L,终末消除半衰期(t½)为13.5–17.1 h,总清除率(CLT)为8.8–10.6 L/h,蛋白结合率为21.3%。
  • 空腹单次口服300 mg(与100 mg静脉给药生物等效)后,Cmax为0.5–0.6 mg/L,AUC0-∞为9.6–11.9 mg·h/L。
  • fAUC24h/MIC被确立为预测奥马环素抗菌疗效的药效学参数。
  • 常见不良反应为轻度、短暂性胃肠道事件,与对照药利奈唑胺和莫西沙星相似。

关键数值与推荐

  • III期试验OASIS-1、OASIS-2和OPTIC分别确立奥马环素相对于利奈唑胺和莫西沙星的非劣效性。
  • FDA已批准奥马环素用于治疗ABSSSI和CABP。

临床怎么用

  • 奥马环素口服剂型可用于静脉转口服序贯治疗,可能促进早期出院、门诊治疗和节约成本。
  • 奥马环素可作为抗菌药物管理计划的一部分,用于治疗耐药和多重耐药革兰阳性(包括MRSA)及革兰阴性病原体引起的感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Omadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Omadacycline remains active against bacterial isolates possessing common tetracycline resistance mechanisms such as efflux pumps (e.g., TetK) and ribosomal protection proteins (e.g., TetM) as well as in the presence of resistance mechanisms to other antibiotic classes. The pharmacokinetics of omadacycline are best described by a linear, three-compartment model following a zero-order intravenous infusion or first-order oral administration with transit compartments to account for delayed absorption. Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects. Oral bioavailability of omadacycline is estimated to be 34.5%. A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L. The free plasma area under concentration-time curve divided by the minimum inhibitory concentration (i.e., fAUC24h/MIC), has been established as the pharmacodynamic parameter predictive of omadacycline antibacterial efficacy. Several animal models including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model have documented the in vivo antibacterial efficacy of omadacycline. A phase II clinical trial on complicated skin and skin structure infection (cSSSI) and three phase III clinical trials on ABSSSI and CABP demonstrated the safety and efficacy of omadacycline. The phase III trials, OASIS-1 (ABSSSI), OASIS-2 (ABSSSI), and OPTIC (CABP), established non-inferiority of omadacycline to linezolid (OASIS-1, OASIS-2) and moxifloxacin (OPTIC), respectively. Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. Phase II clinical trials involving patients with acute cystitis and acute pyelonephritis are in progress. Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profile of omadacycline is similar to studied comparators, linezolid and moxifloxacin. Unlike tigecycline and eravacycline, omadacycline has an oral formulation that allows for step-down therapy from the intravenous formulation, potentially facilitating earlier hospital discharge, outpatient therapy, and cost savings. Omadacycline has a potential role as part of an antimicrobial stewardship program in the treatment of patients with infections caused by antibiotic-resistant and multidrug-resistant Gram-positive [including methicillin-resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020. PMID: 31970713. doi:10.1007/s40265-020-01257-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。